Application of EPO source peptide in preparation of medicine for treating pulmonary fibrosis
By using EPO-derived peptides with amino acid sequence QEQLERALNSS, the treatment of bleomycin-induced pulmonary fibrosis mice has solved the problem that existing anti-fibrotic drugs cannot effectively control lung function damage and have side effects, and achieved significant improvement in lung fiber. and reduce mortality.
Patent Information
- Application Number
- CN202411460441.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-18
- Publication Date
- 2024-11-29
AI Technical Summary
Existing anti-fibrotic drugs such as pirfenidone and nidanib are effective for mild and moderate fibrosis, but cannot fully control or reverse damaged lung function, and are poorly tolerated, have side effects, and lack effective IPF treatment methods.
EPO-derived peptides with amino acid sequence QEQLERALNSS were used to treat bleomycin-induced pulmonary fibrosis mice. Treatment was performed by intraperitoneal injection, which significantly improved pulmonary fibrosis lesions and reduced mortality, avoiding blood red blood cells treated with EPO and Side effects of thrombosis.
EPO-derived peptide treatment significantly improved lung fibrosis in mice with pulmonary fibrosis, reduced mortality and thrombosis risk, and had no side effects, providing potential new drugs for IPF treatment.
Smart Images

Figure CN119033913A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine and provides application of EPO-derived peptides in preparing medicines for treating pulmonary fibrosis. Background Art
[0002] Idiopathic pulmonary fibrosis (IPF) is a special form of chronic progressive fibrosing pneumonia with unknown etiology. IPF is more common in the elderly, with a median age of onset of 65 years. It is mainly manifested by progressive dyspnea, accompanied by restrictive ventilation dysfunction and gas exchange disorders, leading to hypoxemia and even respiratory failure. IPF has an insidious onset, and its course continues to progress, is unpredictable and irreversible. There is currently a lack of effective treatments, and its prognosis is usually poor. The median survival time of patients is only 3-5 years, and the five-year survival rate is estimated to be about 20%, which is even lower than the survival rate of many types of cancers. It is called "cancer that is not cancer."
[0003] From 2015 to 2022, the number of IPF patients worldwide increased from 1.4 million to 1.7 million, and is expected to reach 1.8 million by 2023. The number of IPF patients is expected to increase as the aging population continues to increase worldwide, the number of patients with lung infections caused by viral infections in recent years, the popularization of diagnosis, and smoking.
[0004] IPF patients are basically incurable, and the main purpose of treatment is to delay disease progression and improve patients' quality of life. Currently, anti-fibrotic drugs have become the main treatment for IPF. There are two drugs approved for the treatment of IPF, namely Pirfenidone and Nintedanib. These two drugs are effective for mild and moderate fibrosis and can delay the decline of lung function, but cannot completely control or reverse damaged lung function. In addition, these two drugs are poorly tolerated and have side effects (such as gastrointestinal intolerance, phototoxicity, and hepatotoxicity), which may lead to treatment interruption. Therefore, it is necessary to develop new drugs for the treatment of IPF.
[0005] Erythropoietin (EPO) is the most important hematopoietic factor in the body, but current studies have found that EPO also has a variety of non-hematopoietic functions, such as promoting damage repair, inflammation inhibition, etc. Although studies have found that EPO can reduce pulmonary fibrosis in IPF animal models (bleomycin-induced pulmonary fibrosis in mice), given that the important function of EPO is to promote the production of red blood cells and platelets, and hypoxemia caused by IPF can also increase blood red blood cells, etc.; and the increase in blood red blood cells and platelets will promote blood coagulation, increase thrombosis, and cause serious side effects such as death of the body. Therefore, the present invention will explore the potential side effects of EPO treatment of pulmonary fibrosis and verify the therapeutic effect of an EPO-derived peptide on pulmonary fibrosis. Summary of the invention
[0006] In view of this, the object of the present invention is to provide the use of EPO-derived peptides in the preparation of drugs for treating pulmonary fibrosis.
[0007] To achieve the above object, the present invention provides the following technical solutions:
[0008] 1. Use of an EPO-derived peptide in the preparation of a drug for treating pulmonary fibrosis, wherein the amino acid sequence of the EPO-derived peptide is: QEQLERALNSS, as shown in SEQ ID NO.1.
[0009] 2. Use of a polynucleotide encoding an EPO-derived peptide in the preparation of a drug for treating pulmonary fibrosis, wherein the amino acid sequence of the EPO-derived peptide is: QEQLERALNSS, as shown in SEQ ID NO.1.
[0010] 3. Use of a pharmaceutical composition comprising an EPO-derived peptide or a polynucleotide encoding an EPO-derived peptide in the preparation of a drug for treating pulmonary fibrosis, wherein the amino acid sequence of the EPO-derived peptide is: QEQLERALNSS, as shown in SEQ ID NO.1.
[0011] 4. A pharmaceutical composition comprising an EPO-derived peptide or a polynucleotide encoding an EPO-derived peptide, wherein the amino acid sequence of the EPO-derived peptide is: QEQLERALNSS, as shown in SEQ ID NO.1.
[0012] 5. A drug for treating pulmonary fibrosis, wherein the active ingredient is an EPO-derived peptide or a polynucleotide encoding an EPO-derived peptide, wherein the amino acid sequence of the EPO-derived peptide is: QEQLERALNSS, as shown in SEQ ID NO.1.
[0013] The beneficial effects of the present invention are:
[0014] The applicant found that although EPO treatment of mice with bleomycin-induced pulmonary fibrosis significantly improved the pulmonary fibrosis lesions of mice, the weight loss and mortality of the mice were not improved compared with the control group, and the number of red blood cells, hemoglobin content, coefficient of variation of red blood cell distribution width and pulmonary vascular embolism of EPO-treated mice were significantly higher than those of the control group. This shows that although EPO treatment can improve pulmonary fibrosis in mice with pulmonary fibrosis, it has serious side effects and cannot improve the overall condition of patients with pulmonary fibrosis or reduce mortality, and is not suitable for the treatment of IPF.
[0015] The present invention uses an EPO-derived peptide to treat bleomycin-induced pulmonary fibrosis mice, which not only significantly improves the pulmonary fibrosis lesions of the mice, but also significantly improves the weight loss and increased mortality of the mice. At the same time, there are no significant differences in the number of red blood cells, hemoglobin content, coefficient of variation of red blood cell distribution width and pulmonary vascular embolism of the mice treated with the EPO-derived peptide compared with the control group, indicating that the EPO-derived peptide treatment can not only significantly improve the pulmonary fibrosis lesions of the mice with pulmonary fibrosis, but also has no side effects, can improve the overall condition of patients with pulmonary fibrosis, and significantly reduce the mortality rate, providing a potential new drug for the treatment of IPF.
[0016] Other advantages, objectives and features of the present invention will be described in the following description to some extent, and to some extent, will be obvious to those skilled in the art based on the following examination and study, or can be taught from the practice of the present invention. The objectives and other advantages of the present invention can be realized and obtained through the following description. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] In order to make the purpose, technical solutions and advantages of the present invention more clear, the present invention will be described in detail below in conjunction with the accompanying drawings, wherein:
[0018] Figure 1 EPO treatment improves bleomycin-induced pulmonary fibrosis in mice, where A is hematoxylin-eosin staining, B is Masson staining, C is the alveolitis score of Figure A, D is the fibrosis score of Figure B, E is the hydroxyproline content, and F is the relative protein expression of α-SMA and col-1 measured by immunoblotting;
[0019] Figure 2 EPO treatment could not improve the overall condition of bleomycin-induced mice, and promoted hematopoiesis and vascular thrombosis. A is the survival rate of mice in different groups at 21 days, B is the weight change of mice in different groups at 21 days, C is the number of red blood cells in different groups, D is the hemoglobin content in different groups, E is the coefficient of variation of red blood cell distribution width in different groups, and F is hematoxylin-eosin staining to see thrombus;
[0020] Figure 3 EPO-derived peptide treatment improved bleomycin-induced pulmonary fibrosis in mice, where A is hematoxylin-eosin staining, B is Masson staining, C is the alveolitis score of Figure A, D is the fibrosis score of Figure B, E is the hydroxyproline content, and F is the relative protein expression of α-SMA and col-1 measured by immunoblotting;
[0021] Figure 4The EPO-derived peptide treatment improved the overall condition of mice induced by bleomycin, and did not promote hematopoiesis and vascular thrombosis in mice. A is the survival rate of mice in different groups for 21 days, B is the weight change of mice in different groups for 21 days, C is the number of red blood cells in different groups of mice, D is the hemoglobin content in different groups of mice, E is the coefficient of variation of red blood cell distribution width in different groups of mice, and F is hematoxylin-eosin staining to see thrombus; DETAILED DESCRIPTION
[0022] The present invention will be further described below in conjunction with specific implementation modes.
[0023] Reference Examples
[0024] Synthesis of EPO-derived peptide (i.e., Ipretide)
[0025] The amino acid sequence of the EPO-derived peptide is: QEQLERALNSS, as shown in SEQ ID NO.1.
[0026] The synthesis method of EPO-derived peptides uses the standard fluorenylmethoxycarbonyl (Fmoc) protocol, and arginine is coupled twice. The specific method is as follows:
[0027] Initially, 0.125mmol of p-hydroxymethylphenoxymethyl polystyrene resin (HMP resin) was selected, and the peptide chain was extended from the carboxyl end to the amino end one by one according to the polypeptide sequence. The amount of each amino acid was 0.5mmol, and the molar ratio with the resin was 4:1. The α-amino acid of each amino acid was Fmoc protected, and the remaining side chain protecting groups were: Ser (tBu), Glu (OtBu), Arg (Pmc). The first amino acid was connected to the resin with 4-lutidine, and the amino acid was activated with 1-hydroxybenzotriazole and dicyclohexyl carbon. After coupling, the Fmoc protecting group was removed with a 20% piperidine aqueous solution to obtain a resin-crude peptide.
[0028] The resin-crude peptide was mixed in 10 mL of cutting solution A (consisting of 0.75 g of crystalline phenol, 0.25 mL of 1,2-ethanedithiol, 0.5 mL of thioanisole, 0.25 mL of deionized water and 10 mL of trifluoroacetic acid) under ice-water bath conditions. After the temperature of the cutting solution rose to room temperature (25°C), it was stirred for 2 hours to cleave the peptide chain from the resin and remove multiple protective groups at the same time. The reaction mixture was filtered through a G4 glass sand funnel to remove the resin, and the reaction bottle, resin and funnel were repeatedly rinsed with 1 mL of trifluoroacetic acid and 10 mL of dichloromethane. The filtrate was evaporated to 1-2 mL at room temperature and low pressure, and 50 mL of pre-cooled ether was added to evaporate the crude EPO-derived peptide, and stored at -20°C for use. The molecular weight of the crude product was detected by mass spectrometry. If correct, the polypeptide was purified by HPLC. The crude peptide was dissolved in pure water or a small amount of acetonitrile and purified according to the following conditions:
[0029] Mobile phase A: 0.1% trifluoroacetic acid aqueous solution
[0030] Mobile phase B: 0.1% trifluoroacetic acid acetonitrile solution
[0031] Flow rate: 1.0ml / min
[0032] Injection volume: 30μl
[0033] Wavelength: 220nm
[0034]
[0035] Chromatographic column: Venusi MRC-ODS C18 30×250mm
[0036] Finally, the purified solution is freeze-dried into powder in a freeze dryer to obtain pure polypeptide.
[0037] Example 1
[0038] Although EPO treatment of mice with pulmonary fibrosis can significantly improve pulmonary fibrosis, it cannot significantly improve the overall condition of diseased mice or reduce mortality
[0039] Bleomycin was used to establish a mouse pulmonary fibrosis model, and EPO was injected intraperitoneally for treatment. Body weight was measured twice a week. Blood was collected after the experiment to detect the number of red blood cells, hemoglobin content and coefficient of variation of red blood cell distribution width. Lung tissue was collected for HE and Masson staining to detect lung pathological damage and fibrosis. Western blot was used to detect the content of collagen-related proteins to reflect pulmonary fibrosis. Hydroxyproline content was detected to reflect pulmonary fibrosis.
[0040] 1. Animals
[0041] C57 / BL6 mice, male, 6-8 weeks old, weighing 22-26 g, were purchased from Spefoc (Beijing) Biotechnology Co., Ltd. The mice were housed in the SPF animal room of the Experimental Animal Center of the Third Military Medical University.
[0042] 2. Experimental Grouping
[0043] The patients were divided into four groups: control group, control + EPO group, bleomycin group, bleomycin + EPO group
[0044] 3. Establishment of mouse pulmonary fibrosis model
[0045] Take the mouse, anesthetize it with 100 μL of 1% sodium pentobarbital aqueous solution by intraperitoneal injection, fix it on the small animal operation table, hold the forceps in the right hand to pull the tip of the tongue, hold the laryngoscope in the left hand to insert it into the throat, lift the epiglottis, fully expose the glottis, replace the high-pressure atomization needle in the right hand and gently and quickly insert it into the glottis to the carina, and the assistant quickly pushes 50 μL of the pre-prepared bleomycin solution (3 mg / kg), wait for a few seconds, withdraw the needle and scope, and place the mouse on the rewarming blanket to wait for recovery. EPO: 2500 μg / kg, intraperitoneal injection, twice a week. Routine feeding, daily observation of survival, record of weight changes twice a week, medication from the third day of modeling, and sampling on the 21st day.
[0046] 4. Lung pathology staining (HE and Masson staining)
[0047] 4.1 Paraffin embedding and sectioning
[0048] 1) Dehydration: Remove the lung tissue from the fixative, place it in a dehydration box, and soak it in gradient ethanol (volume concentration 75%).
[0049] Ethanol aqueous solution 4 hours - 85% ethanol aqueous solution 2 hours - 90% ethanol aqueous solution 2 hours
[0050] - 95% ethanol in water by volume for 1 hour - 100% ethanol for 1 hour).
[0051] 2) Transparency: Soak in xylene for 1 hour.
[0052] 3) Embedding: Take the embedding frame, add melted paraffin in advance, place the dehydrated lung tissue in it according to the largest cross-section, mark it, cool it in the freezer, take it out and trim it after it is completely solidified.
[0053] 4) Sectioning: Fix the prepared paraffin block on the microtome, slice the paraffin slices in the sagittal plane with a thickness of 5 μm, carefully move the sliced paraffin slices to the warm water tank for slide spreading, pick them up with a glass slide, dry them in a slide drying machine and set them aside.
[0054] 4.2 HE staining (Table 1)
[0055] 1) Paraffin sections were routinely dewaxed to water (xylene immersion, 15 minutes each time - 100% ethanol 2 minutes - 100%
[0056] ethanol for 2 minutes - 95% ethanol aqueous solution for 2 minutes - 75% ethanol aqueous solution for 2 minutes - 50% ethanol aqueous solution for 2 minutes - deionized water for 2 minutes).
[0057] 2) Stain with hematoxylin for 3-5 minutes and wash with tap water.
[0058] 3) Differentiate in acidic ethanol rapid differentiation solution for 5 seconds, and wash with tap water for 10 minutes to turn blue.
[0059] 4) Stain with eosin for 1 minute and wash with tap water.
[0060] 5) Dehydrate, make transparent, and seal the slides with neutral gum.
[0061] Table 1. HE staining pathological scoring criteria
[0062]
[0063] 4.3Masson staining (Table 2)
[0064] 1) Dewax the sections and make them hydrated as in 2.2.3.2.
[0065] 2) Stain with prepared Weigert's hematoxylin for 7 minutes.
[0066] 3) Differentiate in acidic differentiation solution for 10 seconds and wash with distilled water.
[0067] 4) Dye with Masson blue solution for 5 minutes and wash with distilled water.
[0068] 5) Stain with Ponceau fuchsin for 5 minutes.
[0069] 6) Wash with 0.2% acetic acid aqueous solution for 1 minute.
[0070] 7) Differentiate with phosphomolybdic acid for 5 minutes, and wash with 0.2% acetic acid aqueous solution for 1 minute.
[0071] 8) Stain with aniline blue for 10 minutes and wash with 0.2% acetic acid aqueous solution for 1 minute.
[0072] 9) Soak in 95% ethanol aqueous solution for 3 seconds, 100% ethanol for 10 seconds, and xylene for transparency.
[0073] 10) Seal the slides with neutral gum.
[0074] Table 2. Masson staining scoring criteria
[0075]
[0076] 5. Western blot detection of protein levels
[0077] 5.1 Lung tissue protein extraction
[0078] 1) Prepare protein lysis buffer. Add 20 μL each of 50× protease inhibitor (Biyuntian, P1048), phosphatase inhibitor (Biyuntian, P1048), and EDTA (Biyuntian, P1048) to every 1 mL, mix well, and keep on ice for later use.
[0079] 2) Take lung tissue at -80℃, cut about 100 mg with sterilized scissors, put the sample into a 1.5mL EP tube, add 500μL of the prepared lysis solution and 3 stainless steel grinding beads, put it into a tissue freezing grinder precooled to 4℃, grind at 60Hz / min for 6 minutes.
[0080] 3) Move the ground EP tube to a pre-cooled refrigerated centrifuge at 12,000 rpm for 5 minutes. Perform subsequent operations on ice.
[0081] 4) Carefully pipette about 400 μL of the middle layer liquid into a new 1.5 mL EP tube and mark it.
[0082] 5.2 Protein quantification and denaturation
[0083] The Bradford method (Biyuntian, P0006C) was used for quantification.
[0084] 1) Preparation of gradient standards
[0085] 2) Take a 96-well plate, mark the standard wells and the test wells, add different gradient concentrations of standards to the standard wells, and add 10-fold diluted samples to the test wells, the volume is 10 μL, and make one duplicate well for each well.
[0086] 3) Add 300 μL of G250 staining solution to each well.
[0087] 4) Measure the absorbance at a wavelength of 595 nm using an enzyme-labeled instrument.
[0088] 5) Calculate the protein concentration in the sample to be tested based on the standard curve.
[0089] 6) Rewarm the 5× loading buffer in advance, dilute it to 1× with the sample, mix well, place in a metal bath for 15 minutes, cool and divide into portions, and store at -80°C until use.
[0090] 5.3SDS-PAGE gel electrophoresis
[0091] 1) After the long and short glass plates are cleaned and dried with deionized water, the bottoms are aligned, sealed with sealing film, and assembled to ensure that there is no liquid leakage.
[0092] 2) Prepare separation gel and concentration gel according to the gel preparation kit.
[0093] 3) Quickly inject the prepared 10% separation gel solution into the glass plate sandwich, about 4.5 mL for each, press the top flat with isopropanol, and let it stand at room temperature for 20-40 minutes.
[0094] 4) Preparation of stacking gel
[0095] 5) After the separation gel is completely solidified, pour off the isopropanol on top, wash with deionized water three times, then slowly add about 2mL of prepared concentrated gel to fill the groove and overflow, quickly insert the comb, add 500μL of concentrated gel again to reduce the generation of bubbles, and let it stand at room temperature for 20-40 minutes.
[0096] 6) Place the prepared SDS-PAGE gel glass plates in groups of two, with the short plate facing inward, in the electrophoresis cassette as required, then add the prepared electrophoresis buffer to check for leakage. If there is no leakage, gently pull out the comb vertically upward with both hands, and add the protein sample to be tested and the pre-stained protein marker to the corresponding channels using a 10μL or 20μL gun tip according to the principle of equal mass loading. Then place the electrophoresis cassette in the electrophoresis tank according to the principle of positive to positive and negative to negative, and replenish the electrophoresis buffer.
[0097] 7) Electrophoresis parameters: Constant voltage 100V, until the protein marker begins to separate. When the blue indicator reaches about 1-2 cm from the bottom edge of the glass plate, the marker is fully separated and the electrophoresis is stopped.
[0098] 5.4 Transfer
[0099] 1) Cut the PVDF membrane of the target protein band size according to the marker, soak it in 100% ethanol to activate it, and set aside.
[0100] 2) Prepare a transfer sandwich from bottom to top in the order of negative electrode - sponge pad - filter paper pad - gel - PVDF membrane - filter paper pad - sponge pad - positive electrode, use a roller to remove bubbles, put the prepared sandwich into the transfer tank, completely submerge it with pre-cooled transfer solution, and surround it with ice water. The transfer conditions are: constant current (250mA) for 90 minutes.
[0101] 5.5 Antibody incubation and exposure
[0102] 1) After the transfer, move the membrane to an incubation box with blocking solution and incubate it on a horizontal shaker at room temperature for 1 hour.
[0103] 2) Discard the blocking solution and wash once with membrane washing solution for 3 minutes.
[0104] 3) Refer to the instructions for use of the primary antibody, dilute the primary antibody in proportion with the primary antibody diluent, add it to the incubation box with the membrane, and incubate at 4°C overnight.
[0105] 4) Recover the primary antibody, add membrane washing solution, shake horizontally, and wash 3 times, 5 minutes each time.
[0106] 5) Dilute the corresponding secondary antibody with secondary antibody diluent, add to the corresponding membrane incubation box, shake horizontally, at room temperature, for 1 hour.
[0107] 6) Recover the secondary antibody, add membrane washing solution, shake horizontally, and wash 3 times, 5 minutes each time.
[0108] 7) According to the developer instructions, mix equal volumes of solution A and solution B, slightly dry the liquid on the film surface, and evenly drop the prepared developer on the film surface. Expose and develop using a fluorescent imaging system.
[0109] 8) The gray value of protein bands was semi-quantitatively analyzed using Image J.
[0110] 6. Determination of lung hydroxyproline content
[0111] 1) Use the hydroxyproline detection kit (A030-2-1, purchased from Nanjing Jiancheng Bioengineering Institute) and perform sample testing according to the instructions. Accurately weigh 50 mg of lung tissue and put it into a test tube. Accurately add 1 mL of hydrolysis solution and mix well. Cover and hydrolyze at 95°C for 20 minutes.
[0112] 2) Adjust pH: A. Rinse the outside of the test tube with running water, cool it down, add an indicator (10 μl / tube), and mix well. B.
[0113] Add liquid A (1mL / tube), mix well, and the color in the tube turns red. C. Add liquid B (add drop by drop, mix well each time, and wait for a few seconds) until the color of the liquid disappears from red. At this time, the pH value of the liquid is between 6.0-6.8. D. Add ddH2O to each tube, adjust the volume to 10mL, and mix well. E. Take 4mL of hydrolyzate from 10mL, add 0.03g of activated carbon, shake slightly, centrifuge for 10 minutes (3500 rpm), and take 1mL of supernatant as the test solution for testing.
[0114] 3) Sample addition test (Table 3)
[0115] Table 3
[0116]
[0117] 4) After the sample is added, place in a 60°C metal bath for 15 minutes, cool by itself, centrifuge for 10 minutes (3500 rpm), take the supernatant (0.2 mL / tube), take a 96-well plate, add the supernatant, and measure the OD value at 550 nm with an enzyme marker. According to the OD value, calculate the value of Hyp according to the formula:
[0118] Hyp content (μg / mg) = (measured OD value-blank OD value) / (standard OD value-blank OD value)×(5μg / mL)×total volume of hydrolyzate (mL) / tissue wet weight (mg).
[0119] 7. Determination of the coefficient of variation of red blood cells, hemoglobin content and red blood cell distribution width
[0120] After the mice were anesthetized with a 1% sodium pentobarbital aqueous solution, blood was collected from the eyeballs into a routine blood collection tube, mixed by inversion, stored at 4°C, and tested using a Mindray veterinary fully automatic blood cell analyzer (model: BC-5000vet).
[0121] result
[0122] The results are as follows Figure 1 HE staining showed that EPO treatment significantly improved bleomycin-induced lung injury ( Figure 1 Masson staining showed that EPO treatment significantly alleviated bleomycin-induced lung fibrosis ( Figure 1 B and D); and EPO treatment significantly reduced the expression of proline ( Figure 1 Middle E), α-SMA protein and col-1 protein ( Figure 1 The increase of F) content in the middle indicated that EPO treatment significantly improved bleomycin-induced pulmonary fibrosis.
[0123] However, EPO treatment did not improve the increased mortality of mice caused by bleomycin ( Figure 2 A) and weight loss ( Figure 2 B); and the number of red blood cells in EPO-treated mice ( Figure 2 C), hemoglobin content ( Figure 2 D), coefficient of variation of red blood cell distribution width ( Figure 2 E) and pulmonary embolism ( Figure 2 The results in Figure 5 (F) were significantly higher than those in the control group, indicating that EPO treatment can promote hematopoiesis in bleomycin-induced mice, leading to increased thrombosis, but cannot improve the overall condition of mice with pulmonary fibrosis or reduce mortality, and is not suitable for the treatment of IPF.
[0124] Example 2
[0125] EPO-derived peptides were used to treat mice with pulmonary fibrosis, significantly improving the pulmonary fibrosis, the overall condition of the diseased mice, and reducing mortality.
[0126] A mouse pulmonary fibrosis model was established using bleomycin, and the mouse was treated by intraperitoneal injection of the EPO-derived peptide obtained in the reference example. The body weight was measured, and blood was collected after the experiment to detect the number of red blood cells, hemoglobin content, and coefficient of variation of red blood cell distribution width. Lung tissue was taken for HE and Masson staining to detect lung pathological damage and fibrosis; western blot was used to detect the content of collagen-related proteins to reflect pulmonary fibrosis; and the lung hydroxyproline content was detected to reflect pulmonary fibrosis.
[0127] 1. Animals
[0128] C57 / BL6 mice, male, 6-8 weeks old, weighing 22-26 g, were purchased from Spefoc (Beijing) Biotechnology Co., Ltd. The mice were housed in the SPF animal room of the Experimental Animal Center of the Third Military Medical University.
[0129] 2. Experimental Grouping
[0130] The mice were divided into three groups: control group, bleomycin group, and EPO-derived peptide group.
[0131] 3. Establishment of mouse pulmonary fibrosis model
[0132] EPO-derived peptide: 2 mg / kg, intraperitoneal injection, once a day.
[0133] The rest is the same as in Example 1.
[0134] 4. Lung pathology staining (HE and Masson staining)
[0135] Same as Example 1.
[0136] 5. Western blot detection of protein levels
[0137] Same as Example 1.
[0138] 6. Determination of lung hydroxyproline content
[0139] Same as Example 1.
[0140] 7. Determination of the coefficient of variation of red blood cells, hemoglobin content and red blood cell distribution width
[0141] Same as Example 1.
[0142] result
[0143] The results are as follows Figure 3 As shown, HE staining showed that EPO-derived peptide treatment significantly improved bleomycin-induced lung injury ( Figure 3 A and C), Masson staining showed that EPO-derived peptide treatment significantly alleviated bleomycin-induced lung fibrosis ( Figure 3 B and D); and EPO-derived peptide treatment significantly reduced the expression of proline ( Figure 3 Middle E), α-SMA protein and col-1 protein ( Figure 3 The increase in F) content in the middle indicated that EPO-derived peptide treatment significantly improved bleomycin-induced pulmonary fibrosis.
[0144] Moreover, EPO-derived peptide treatment significantly improved the increased mortality of mice caused by bleomycin ( Figure 4 A) and weight loss ( Figure 4 Middle B); At the same time, the number of red blood cells in mice treated with EPO-derived peptides ( Figure 4 C), hemoglobin content ( Figure 4 D), coefficient of variation of red blood cell distribution width ( Figure 4 E) and pulmonary embolism ( Figure 4 F) was not higher than that of the control group, indicating that EPO-derived peptide treatment would not induce hematopoiesis and thrombosis in mice induced by bleomycin, but could improve the overall condition of mice with pulmonary fibrosis and reduce the mortality rate, and was suitable for the treatment of IPF.
[0145] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the purpose and scope of the technical solution, which should be included in the scope of the claims of the present invention.
Claims
1. The use of EPO-derived peptides in the preparation of drugs for treating pulmonary fibrosis, characterized in that: The amino acid sequence of the EPO-derived peptide is: QEQLERALNSS, as shown in SEQ ID NO.
1.
2. Use of a polynucleotide encoding an EPO-derived peptide in the preparation of a drug for treating pulmonary fibrosis, characterized in that: The amino acid sequence of the EPO-derived peptide is: QEQLERALNSS, as shown in SEQ ID NO.
1.
3. Use of a pharmaceutical composition comprising an EPO-derived peptide or a polynucleotide encoding an EPO-derived peptide in the preparation of a drug for treating pulmonary fibrosis, characterized in that: The amino acid sequence of the EPO-derived peptide is: QEQLERALNSS, as shown in SEQ ID NO.
1.
4. A pharmaceutical composition comprising an EPO-derived peptide or a polynucleotide encoding an EPO-derived peptide, characterized in that: The amino acid sequence of the EPO-derived peptide is: QEQLERALNSS, as shown in SEQ ID NO.
1.
5. A drug for treating pulmonary fibrosis, wherein the active ingredient is an EPO-derived peptide or a polynucleotide encoding an EPO-derived peptide, characterized in that: The amino acid sequence of the EPO-derived peptide is: QEQLERALNSS, as shown in SEQ ID NO.1.
Citation Information
Cited By
A20 derived peptide and application thereof in prevention and treatment of fibrosis and cardiovascular diseases
CN122427251A
